{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:34:22Z","timestamp":1791513262149,"version":"4.3.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["ISS#218362"],"award-info":[{"award-number":["ISS#218362"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study examined cabotegravir (CAB) and rilpivirine (RPV) distribution and HIV suppression in genital and rectal compartments after switching to long-acting intramuscular CAB + RPV administered every two months. At month 4, drug concentrations were measured in blood plasma, seminal plasma (SP), rectal tissue (RT), and cervicovaginal fluid (CVF). Thirty-one participants (16 cisgender men, 15 cisgender women) were included. CAB and RPV exhibited different distributions between compartments. Unbound CAB exceeded the EC50 in SP, RT and CVF while unbound RPV exceeded the EC50 in RT and CVF but not in SP. All participants maintained HIV-1 RNA &amp;lt;20 copies\/mL in all matrices.<\/jats:p>\n                  <jats:p>Clinical Trial Registration: EudraCT Number: 2021-006779-41<\/jats:p>","DOI":"10.1093\/infdis\/jiaf551","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:06:26Z","timestamp":1761743186000},"page":"261-266","source":"Crossref","is-referenced-by-count":4,"title":["Cabotegravir and Rilpivirine Concentrations and HIV-1 RNA Suppression in Genital Fluids and Rectum in People with HIV on Long-Acting Intramuscular Cabotegravir Plus Rilpivirine Antiretroviral Therapy"],"prefix":"10.1093","volume":"233","author":[{"given":"Analuz","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-5031","authenticated-orcid":false,"given":"Sof\u00eda","family":"Sc\u00e9vola","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Niub\u00f3","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sykes","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda P","family":"Schauer","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Guevara-Figueras","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Bellvitge Biomedical Research Institute (IDIBELL) , L'Hospitalet del Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Piatti","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Morenilla","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Sed\u00f3","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Soriano","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2021-891X","authenticated-orcid":false,"given":"Daniel","family":"Medina","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tiraboschi","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Saumoy","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie L","family":"Cottrell","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-1952","authenticated-orcid":false,"given":"Arkaitz","family":"Imaz","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona , L\u2019Hospitalet de Llobregat, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026031304545619500_jiaf551-B1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2026031304545619500_jiaf551-B2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/COH.0b013e32835fc68a","article-title":"Overcoming pharmacologic sanctuaries","volume":"8","author":"Cory","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"2026031304545619500_jiaf551-B3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","article-title":"The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review","volume":"402","author":"Broyles","year":"2023","journal-title":"Lancet"},{"key":"2026031304545619500_jiaf551-B4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(25)00765-2","article-title":"Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis","volume":"406","author":"Dugdale","year":"2025","journal-title":"Lancet"},{"key":"2026031304545619500_jiaf551-B5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2026031304545619500_jiaf551-B6","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2026031304545619500_jiaf551-B7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026031304545619500_jiaf551-B8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3851\/IMP1919","article-title":"Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract","volume":"16","author":"Else","year":"2011","journal-title":"Antivir Ther"},{"key":"2026031304545619500_jiaf551-B9","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","author":"Imaz","year":"2016","journal-title":"J Infect Dis"},{"key":"2026031304545619500_jiaf551-B10","doi-asserted-by":"crossref","first-page":"e1991-9","DOI":"10.1093\/cid\/ciaa1416","article-title":"Dynamics of the decay of human immunodeficiency virus (HIV) RNA and distribution of bictegravir in the genital tract and Rectum in antiretroviral-naive adults living with HIV-1 treated with bictegravir\/emtricitabine\/tenofovir alafenamide (Spanish HIV\/AIDS research network, PreEC\/RIS 58)","volume":"73","author":"Imaz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026031304545619500_jiaf551-B11","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/bcp.14980","article-title":"Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis","volume":"88","author":"Shaik","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026031304545619500_jiaf551-B12","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jac\/dku018","article-title":"Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy","volume":"69","author":"Mora-Peris","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026031304545619500_jiaf551-B13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/cid\/cix358","article-title":"Viral kinetics in semen with different antiretroviral families in treatment-naive human immunodeficiency virus-infected patients: a randomized trial","volume":"65","author":"Gutierrez-Valencia","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026031304545619500_jiaf551-B14","doi-asserted-by":"crossref","first-page":"e748","DOI":"10.1093\/cid\/ciac676","article-title":"Human immunodeficiency virus type 1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir plus rilpivirine: a longitudinal study","volume":"76","author":"Masi\u00e1","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031304545619500_jiaf551-B15","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/infdis\/jiad580","article-title":"Efficacy, safety, and pharmacokinetics by body mass Index category in phase 3\/3b long-acting cabotegravir plus rilpivirine trials","volume":"230","author":"Elliot","year":"2024","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf551\/65050419\/jiaf551.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/261\/65050419\/jiaf551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/261\/65050419\/jiaf551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:56:50Z","timestamp":1773392210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/2\/261\/8307550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf551","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,10,31]]}}}